Navigation Links
UTMB receives $3.2 million to continue collaborative research on cancer in Texas
Date:3/7/2014

The Cancer Prevention and Research Institute of Texas has awarded the University of Texas Medical Branch at Galveston more than $3.2 million to continue a program aimed at creating a new state resource a trove of population research on cancer treatments and outcomes in Texas.

One of 11 multi-investigator research continuation grants recently announced by CPRIT, the UTMB award will fund the work of the organization Comparative Effectiveness Research on Cancer in Texas for two more years.

Led by Dr. James Goodwin, vice president and chief research officer at UTMB, CERCIT is a multidisciplinary consortium of investigators from UTMB, the University of Texas MD Anderson Cancer Center, Rice University and the Texas Cancer Registry.

CERCIT researchers are studying how screening for breast, colon and prostate cancer is conducted throughout the state. They are looking at how access to care and quality of cancer care affect patient outcomes. They are investigating how long health care providers carry out surveillance of cancer survivors.

"This has been a very rich collaboration. The investigators from these institutions work well together," said Goodwin. "Our different disciplines and skill sets create great synergy, not only in research, but also in training the next generation of cancer investigators."

CERCIT was originally funded by CPRIT in 2010. Since then, the organization has become a major presence in Texas's cancer research community.

One of its research projects culminated in the development of a white paper on cancer statistics among Hispanics in Texas distributed to 1,000 legislators and influential individuals and organizations in the Hispanic community nationwide. This is the first time any such research had ever been compiled and disseminated.

Over the course of its first four years, CERCIT has trained 24 new cancer researchers and published more than 80 peer-reviewed cancer studies in such
'/>"/>

Contact: Molly Dannenmaier
mjdannen@utmb.edu
409-771-5105
University of Texas Medical Branch at Galveston
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Loyola Cancer Center receives Outstanding Achievement Award
2. MU receives national award for using mind-body approach to improve health
3. Neuropsychologist receives University of Houstons highest faculty honor
4. Boston researcher, surgical oncologist receives national award
5. LA BioMed receives Grand Challenges Explorations grant
6. Lawson researcher receives 1 of first-ever Pfizer Psychiatry Research Awards
7. Dr. Arthur Slutsky, vice-president of research at St. Michaels, receives lifetime award
8. UC San Diego Superfund Research Program receives $15 million grant renewal
9. Markey receives $6.25 million to study deadly blood and bone marrow disease
10. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
11. UC Santa Barbaras Kavli Institute receives 2 grants to explore interface of physics and biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... three months the trends for evening dresses shift ... one of the hottest styles in the next few months.” ... releases 26 A-line sweetheart evening dresses, and announces the availability ... are trying our best to help a lady to show ... affordable prices, we provide discounted delivery costs to our customers ...
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional ... all of the models at LunaDress.co.uk come with big discounts, up ... wedding veil can turn out to be a most exciting memory ... can always bring surprise to a wedding. On the updated fashion ... choose veils for a big day . , Going out with ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... screening for disease detection, better surgical techniques available to ... reduce the risk of relapse in patients with both ... to dramatic improvements in breast cancer,s survival rates, according ... at The University of Texas MD Anderson Cancer Center. ...
... HOUSTON - Long associated with a worse outcome, researchers ... have discovered that women treated for breast cancer while ... trend for improved overall survival compared to non-pregnant women ... professor in MD Anderson,s Department of Breast Medical Oncology, ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Sept. ... a progestin hormone may be an effective treatment for ... By delaying a total hysterectomy, which is the ... to remain fertile and possibly to have families, according ...
... Reporter , WEDNESDAY, Sept. 29 (HealthDay News) -- A ... knee pain from osteoarthritis, researchers are reporting. But ... phase 3 trial of the drug after 16 patients ... researcher Dr. Nancy E. Lane, director of the Aging ...
... at the University of California, San Diego shows that California,s ... rates that are nearly 25 percent lower than other states. ... population surveys was reassuring" said John P. Pierce, PhD, Sam ... Family and Preventive Medicine at UCSD School of Medicine and ...
... 28, 2010 Although first responders willingly put themselves in ... not be as willing if the disaster is a potentially ... Columbia University,s Mailman School of Public Health found that more ... they surveyed might be absent from work during a serious ...
Cached Medicine News:Health News:MD Anderson study finds increases in 5-, 10-year survival at every stage of breast cancer 2Health News:MD Anderson study finds increases in 5-, 10-year survival at every stage of breast cancer 3Health News:MD Anderson study finds increases in 5-, 10-year survival at every stage of breast cancer 4Health News:UT MD Anderson study finds women treated for breast cancer while pregnant have improved survival 2Health News: IUD Proposed to Treat Uterine Cancer 2Health News: IUD Proposed to Treat Uterine Cancer 3Health News:Novel Drug Eases Osteoarthritis Knee Pain 2Health News:California's leadership in tobacco control results in lower lung cancer rate 2Health News:Less than half of essential workers willing to report to work during a serious pandemic 2Health News:Less than half of essential workers willing to report to work during a serious pandemic 3
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 ... Pharmaceuticals, Inc. today announced that the Committee for Medicinal ... Agency (EMA) has adopted a positive opinion for the ... of adult men with Peyronie,s disease with a palpable ... at the start of therapy. The use ...
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Company remains committed to speeding innovation ... pipeline boasts 70 potential medicines in clinical development, including 33 in ... ten potential new medicines in Phase III by the end of ... such as neuroscience, diabetes and oncology, as well as new areas ...
... MISSISSAUGA, Ontario, June 30, 2011 Valeant Pharmaceuticals ... VRX) announced today that its subsidiary, Valeant International ... acquire rights to both Elidel (pimecrolimus 1% cream) ... Meda, an international specialty pharmaceutical company (listed on ...
Cached Medicine Technology:Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 2Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 3Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 4Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 5Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 6Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 7Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 8Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 10Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 11Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 12Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 13Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 14Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 15Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 16Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™ 2Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™ 3
15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle. Designated most popular model or size....
Grooved roller, on which knife oscillates....
... blade. 17 mm wide blade. ... inches. Note: Has Marcks attachment ... to any thickness up to ... thicker grafts or split graft. ...
5 mm small, sharp, protected blade. Angled at 105 degrees. Flat handle. Designated most popular model or size....
Medicine Products: